Weak Trigger
now
Achieves upgraded fiscal guidance as high-margin intravenous immunoglobulin (IVIG) portfolio sales beat consensus estimates across plasma collection centers.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |